BioSpace News Archive

CB Scientific. Inc. The company has announced that they have engaged MaloneBailey LLP, a certified public accounting firm in Houston, Texas. MaloneBailey LLP to audit financial statements of CBSC and its subsidiaries

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, announced the appointment of Gitanjali Jain as Vice President, Investor Relations and External Affairs.

Exscientia plc announced the closing of its previously-announced upsized initial public offering in the United States of 15,927,500 American Depositary Shares representing 15,927,500 ordinary shares, including 2,077,500 ADSs sold pursuant to the full exercise of the underwriters’ previously granted option to purchase additional ADSs.

Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver a corporate presentation as part of H.C. Wainwright’s 5th Annual NASH Investor Conference.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), announced an upcoming presentation on AT-1501, its lead clinical candidate, at the International Pancreas and Islet Transplantation Association (IPITA) Congress, which is being held virtually from October 20-23, 2021.

Surrozen, Inc. announced that data from its inflammatory bowel disease program, including preclinical studies of SZN-1326 showing colonic mucosal healing in an acute injury model were presented during the 2021 United European Gastroenterology Week.

Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (Rapid Micro), is pleased to announce the appointment of veteran life sciences executive Andy Keys to the newly created position of Chief Commercial Officer (CCO).

Xenon Pharmaceuticals Inc., a clinical stage biopharmaceutical company, announced the pricing of its underwritten public offering of 8,474,577 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 1,694,915 common shares pursuant to its existing shelf registration statement.

ENDRA Life Sciences to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to 11 new employees.